OncoMatch/Clinical Trials/NCT05884320
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Is NCT05884320 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab Govitecan for gland.
Treatment: Sacituzumab Govitecan — To learn if sacituzumab govitecan can help to control salivary gland cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Biomarker criteria
Allowed: HER2 (ERBB2) amplification
Allowed: HER2 (ERBB2) overexpression (3+ by ihc)
Disease stage
Metastatic disease required
Grade: intermediatehigh
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: HER2-targeted therapy — R/M HER2+ tumors only
HER2 overexpressing (3+ by IHC) or amplified tumors, must have received at least one prior line with a HER2-targeting agent OR must have a contra-indication for HER-2 targeted therapy
Cannot have received: radiation therapy
Prior radiation therapy (or other non-systemic therapy) within 2 weeks prior to enrollment
Cannot have received: chemotherapy
Exception: Cohort 2: up to 3 lines of palliative chemotherapy in the R/M setting allowed
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Cannot have received: immunotherapy
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Cannot have received: investigational agent
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Lab requirements
Blood counts
hemoglobin ≥ 9 g/dl; absolute neutrophil count ≥ 1 x 10^9/ml without growth factor support for 28 days; platelets ≥ 100 x 10^9/ml without platelet transfusion for 28 days
Kidney function
creatinine clearance ≥ 30 ml/min as assessed by the cockcroft-gault equation
Liver function
ast and alt ≤ 2.5 x uln or ≤ 5 x uln in patients with liver metastases; total bilirubin ≤ 1.5 x uln or ≤ 3.0 x uln and primarily unconjugated if patient has a documented history of gilbert's syndrome or genetic equivalent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05884320 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, chemotherapy, immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify